Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LINC00173.v1 antisense LNA GapmeR
- Development stage
- Preclinical
- Lead developer
- Exiqon
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal
01
Overview
LINC00173.v1 antisense LNA GapmeR is a research-stage antisense oligonucleotide (ASO) developed by Exiqon. It is designed using Locked Nucleic Acid (LNA) technology in a gapmer configuration to specifically target and facilitate the degradation of the long noncoding RNA (lncRNA) LINC00173.v1. This lncRNA is highly expressed in lung squamous cell carcinoma (SQC) and plays a critical role in promoting angiogenesis and tumor cell proliferation. By silencing LINC00173.v1, the GapmeR inhibits vascular endothelial cell migration and tumorigenesis. Preclinical studies have demonstrated its efficacy in mouse models of lung cancer when administered intraperitoneally.
- Other names
- LINC00173.v1 LNA GapmeRLINC-00173.v1 LNA GapmeRLINC 00173.v1 LNA GapmeRLINC00173.v1 antisense oligonucleotideLINC-00173.v1 antisense oligonucleotideLINC 00173.v1 antisense oligonucleotide
02
Targets
NAGK (N-acetylglutamate kinase)
Beyond the preview
Go deeper on LINC00173.v1 antisense LNA GapmeR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LINC00173.v1 antisense LNA GapmeR.